October 13, 2016 @ 7:44 pm | ABT, Jubak Picks Portfolio, Sell |
Back on September 20 I questioned whether management at Abbott Laboratories had the skills to execute a growth through acquisitions strategy. At the time the company was–and it still is–involved in a dispute with Allere (ALR) over whether that company had...
September 19, 2016 @ 7:36 pm | ABT, Breaking News, Jubak Top 50 Portfolio, Sell |
Where do you find growth in a low-growth economy? If Wall Street projections are correct, the about-to-close third quarter of 2016 will show a 2% year-over-year drop in earnings for the Standard & Poor’s 500 companies–the sixth consecutive quarterly...
September 23, 2010 @ 4:45 pm | ABT, Buy |
At current prices I think you’re getting two of Abbott Laboratories (ABT) most interesting growth opportunities at a deep discount. Abbott is a good mainstream pharmaceutical company. Abbott’s blockbuster drugs include Humira (for rheumatoid and psoriatic arthritis:...